Table 3. Frequency of adverse events per type of treatment.
| Treatment A n = 38 | Treatment B n = 29 | Treatment C n = 36 | |||
|---|---|---|---|---|---|
| Signs and symptoms | % | % | % | ||
| General symptoms | Headache | – | – | – | |
| Cardiovascular | Palpitation | – | – | – | |
| Tachycardia | – | – | – | ||
| Digestive | Nausea | – | – | – | |
| Musculoskeletal | Arthralgia | – | – | – | |
| Myalgias | 2.6 | – | 2.8 | ||
| Nervous | Depression | – | – | – | |
| Dizziness | – | – | – | ||
| Nervousness | – | – | 2.8 | ||
| Local symptoms | Pain | 18.4 | 24.1 | 16.6 | |
| Induration | – | – | 2.8 | ||
| Edema | – | – | – | ||
| Special senses | Blurred vision | – | – | – | |
| Urogenital | Increase of endometrial thickness | 2.6 | – | – | |
| Pelvic inflammation | – | – | – | ||
| Mastalgia | 2.6 | – | – | ||
A: 0.5 mg E + 15 mg P; B: 1.0 mg E + 20 mg P; C: 1.0 mg E + 30 mg P.